| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
43,198 |
41,415 |
$2.23M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,501 |
15,131 |
$988K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
10,783 |
10,765 |
$678K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
6,474 |
6,319 |
$245K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,166 |
2,161 |
$103K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,055 |
1,053 |
$91K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
7,409 |
7,310 |
$70K |
| 81025 |
|
12,486 |
12,151 |
$61K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,688 |
1,678 |
$48K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
112 |
112 |
$43K |
| 81002 |
|
17,013 |
16,610 |
$33K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
5,440 |
5,178 |
$33K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,195 |
1,274 |
$20K |
| 90715 |
|
438 |
435 |
$10K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,355 |
1,334 |
$5K |
| 99201 |
|
155 |
155 |
$5K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
14 |
14 |
$5K |
| 10060 |
|
80 |
80 |
$4K |
| 99215 |
Prolong outpt/office vis |
53 |
53 |
$4K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
150 |
149 |
$4K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
4,405 |
4,271 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
395 |
389 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
294 |
293 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
3,078 |
3,048 |
$2K |
| 93000 |
|
288 |
284 |
$2K |
| 12001 |
|
26 |
26 |
$958.54 |
| 87400 |
|
103 |
103 |
$844.81 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
125 |
123 |
$416.19 |
| 82962 |
|
136 |
132 |
$250.30 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
348 |
335 |
$220.34 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
40 |
39 |
$85.69 |
| S9083 |
Global fee urgent care centers |
6,837 |
6,512 |
$5.40 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
230 |
228 |
$3.45 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
27 |
27 |
$0.11 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
87 |
87 |
$0.00 |